#### **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 28, 2023

#### SAGIMET BIOSCIENCES INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-41742 (Commission File Number)

Sagimet Biosciences Inc. 155 Bovet Road, Suite 303, San Mateo, California 94402 (Address of principal executive offices, including zip code)

20-5991472 (I.R.S. Employer Identification No.)

(650) 561-8600

(Registrant's telephone number, including area code)

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u> Series A Common Stock, \$0.0001 par value per share

<u>Trade</u> <u>Symbol(s)</u> SGMT

Name of each exchange on which registered The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Financial Officer

On December 28, 2023, Anthony Rimac provided notice of his intent to step down as the Chief Financial Officer of Sagimet Biosciences Inc. (the "<u>Company</u>") effective January 31, 2024. Mr. Rimac resigned for personal reasons and not as a result of any disagreement with the Company or its independent registered public accountants on any matter relating to the Company's financial or accounting operations, policies or practices.

The Company has retained Stout, a global advisory firm specializing in corporate finance, accounting and transaction advisory services, to provide interim support during the transition period. Gaeton Biscardi, Managing Director of Stout, will be serving as the Company's Interim VP of Finance during this transition period, and Joe Oriti, Director of Stout, will provide his services as a consultant during the period. Contingent on the approval of the Company's Board of Directors (the "Board"), the Company intends to appoint Mr. Oriti as Interim Principal Financial Officer of the Company following Mr. Rimac's departure to serve in such role while the Board conducts a search of potential candidates to replace Mr. Rimac.

#### Item 7.01 Regulation FD Disclosure.

On December 29, 2023, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit		
No.	Document	
<u>99.1</u>	Investor Presentation of Sagimet Biosciences Inc., dated December 29, 2023.	
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).	

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Sagimet Biosciences Inc.

By: /s/ David Happel David Happel Chief Executive Officer

Date: December 29, 2023

# SAGIMET

Targeting Metabolic Dysfunction with Novel Therapies to Treat NASH, Acne and Cancer

December 2023


# Forward Looking Statements

2

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe har of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than sta historical facts or statements that relate to present facts or current conditions, including but not limited to, state possible or assumed future results of operations, business strategies, research and development plans, regulatory market opportunity, competitive position and potential growth opportunities are forward-looking statements. The involve known and unknown risks, uncertainties and other important factors that may cause our actual results, pe achievements to be materially different from any future results, performance or achievements expressed or impl forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "believe," "estimate," "predict," "po "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this pr only predictions. These forward-looking statements speak only as of the date of this presentation and are subject risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are be control, including, among others: the clinical development and therapeutic potential of denifanstat or any other c we may develop; our ability to advance drug candidates into and successfully complete clinical trials, including ou Phase 2b clinical trial; our relationship with Ascletis, and the success of its development efforts for denifanstat; th our estimates regarding our capital requirements; and our ability to maintain and successfully enforce adequate in property protection. These and other risks and uncertainties are described more fully in the "Risk Factors" section may not be achieved or occur, and actual results could differ materially from those projected in ou Proven Team with Development and Commercialization Experience / Hepatology, Metabolic Disease and Oncology

65	Dave Happel President & CEO	<ul> <li>Cognoa: President &amp; CEO Chrono Therapeutics: President &amp; CEO Senior Executive and Commercial roles at Horizon, Raptor, Dynavax, Chiron</li> <li>M.B.A. – Indiana State University; B.A. Chemistry – Indiana University</li> </ul>	i Hor
3	George Kemble Executive Chairman	<ul> <li>AstraZeneca (formerly MedImmune, Aviron): SVP Research for Biologics &amp; General Manager of California operations, VP Vaccine Research &amp; Development for Vaccines</li> <li>Ph.D. – Stanford University, Dept of Microbiology &amp; Immunology</li> </ul>	AstraZene
	Eduardo Martins	<ul> <li>Abbvie (formerly Allergan), Eiger BioPharmaceuticals, Gilead, Genentech, Dynavax, Intermune, SciClone</li> </ul>	abbv
	СМО	<ul> <li>D.Phil. – University of Oxford</li> <li>M.D. – Federal University of Rio de Janeiro, Brazil</li> </ul>	Genen
	CMO Anthony Rimac CFO		Genen Cogn

# Sagimet Investment Highlights




# **Development Pipeline: Indications and Clinical Milestones**




5 \* Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China

# NASH: A Burgeoning Epidemic



# Denifanstat in NASH


# Denifanstat: Differentiated Mechanism Believed to Target Key Driver



Adapted from Wegermann et al, Clinical Liver Disease, Vol 11, No 4, April 2018, DOI: 10.1002/cld.709

8

## Denifanstat Showed Dose-Dependent Reduction of Liver Fat in FASCINAT Improved Key Drivers of NASH and Metabolic Health




9

- No dose-related significant adverse events relative to placebo
- No serious AEs

#### • Majority of AEs were Grade 1; no Grade ≥3 drug-related AEs

	Cohort 1			Cohort 2		Cohoi	
Treatment Emergent Adverse Event (TEAE) Classification	US Placebo N=31	US 25mg N=33	US 50 mg N=35	China Placebo N=9	China 50 mg N=21	US 75m N=1	
Any TEAE	Gr 1: 12 (38.7%) Gr 2: 7 (22.6%)	Gr 1: 18 (54.5%) Gr 2: 7 (21.2%)	Gr 1: 12 (34.3%) Gr 2: 6 (17.1%)	Gr 1: 3 (33%) Gr 2: 2 (22%)	Gr 1: 11 (52%) Gr 2: 4 (19%) Gr 3: 2 (10%)	Gr 1: 3 ( Gr 2: 6 (	
TEAE leading to drug withdrawal	0	2 (6.1%)	0	0	0	4 (319	
Treatment Emergent Serious Adverse Event (SAE)	0	0	0	0	0	0	
Drug related TEAE	Gr 1: 3 (9.7%) Gr 2: 1 (3.2%)	Gr 1: 10 (30.3%) Gr 2: 2 (6.1%)	Gr 1: 9 (25.7%) Gr 2: 1 (2.9%)	0	Gr 1: 9 (43%) Gr 2: 4 (19%)	Gr 1: 1 ( Gr 2: 6 (4	

# Phase 2b Biopsy Trial: Measuring Histological Improvement



 Prespecified interim analysis of the first 52 patients with MRI-PDFF >8%

#### Primary endpoints (biopsy)

- NAS ≥2 points improvement w/o worsenin OR NASH resolution + NAS ≥2 improvement w, worsening of fibrosis
- 2. Safety

#### Secondary endpoints

- Improvement in liver fibrosis ≥1 stage wit worsening of NASH (Bx)
- Digital AI pathology
- Interim MRI-PDFF: absolute decrease, % ( from baseline, % pts ≥30% (responders)

# Interim Analysis Cohort Represents Target Patient Population

FASCINATE-2 Phase 2b Interim Analysis Demographics					
Mean (SD)	Placebo (22)	Denifanstat (30)	Combined		
Age (years)	56.8 ( 9.4)	56.1 (12.4)	56.4 (11.1)		
Female/Male (%)	14 (63.6%) / 8 (36.4%)	17 (56.7%) / 13 (43.3%)	31 (59.6%) / 21 (40.4%)		
Not Hispanic or Latino	16 (72.7%)	24 (80.0%)	40 (76.9%)		
Weight (kg)	97.8 (21.9)	100.9 (21.2)	99.6 (21.4)		
Diabetes (% T2DM)	13 (59.1%)	21 (70.0%)	34 (65.4%)		
F2/F3 (%)	12 (54.5%) / 10 (45.5%)	12 (40.0%) / 18 (60.0%)	24 (46.2%) / 28 (53.8%)		
MRI-PDFF (%)	21.78 (5.46)	17.46 (6.36)	19.29 (6.32)		
Fibroscan (kPa)	10.67 ( 4.07)	12.29 ( 7.33)	11.56 ( 6.04)		
ALT (U/L)	69.77 (42.50)	57.14 (27.55)	62.70 (35.11)		
AST (U/L)	51.00 (29.87)	44.43 (22.65)	47.32 (26.00)		
LDL (mg/dL)	111.37 (40.6)	96.29 (50.27)	102.86 (46.4)		
ELF	9.70 ( 0.76)	9.73 ( 0.76)	9.72 (0.75)		
PRO-C3 cobas® (ng/mL)	35.72 (15.71)	32.54 (11.19)	33.91 (13.28)		

- Typical F2/F3 NASI
- Middle-aged
- High % of diabete
- High liver fat by M
- Elevated liver enzy inflammation
- Non-invasive mark consistent with F2


12

FASCINATE-2 Interim Results Consistent with Comprehensive Positive Readouts from FASCINATE-1

 FASCINATE-2 interim analysis showed consistent improvements in key drivers of NASH as observed in FASCINATE-1

Mechanism	Biomarker
1 Steatosis	Liver fat (MRI-PDFF)
2 Inflammation/lipotoxicity	ALT, CK-18, ceramides
3 Fibrosis	PRO-C3, ELF


- Improvements observed in multiple biomarkers of
   4 metabolic health
  - LDL-cholesterol
  - FGF-21




Biomarkers replicated in FASCINATE-2

# Denifanstat Decreased Liver Fat


Responders Correlate with Liver Biopsy Improvement



# Denifastat Decreased PRO-C3 and ELF – Suggests Fibrosis Red



# Denifanstat Improved Markers of Cardiometabolic Health



# Denifanstat Passed Planned IDMC Safety Review in FASCINATE

### Sagimet is blinded to data



#### • All randomized subjects: blinded data set including active and placebo

- Majority of AEs to date were Grade 1 or 2; no Grade ≥3 drug-related AEs
- A planned safety review of unblinded data from all 168 patients conducted by Independent Data Monitor


   no concerns

FASCINATE-2 Phase 2b - Blinded data set				
Treatment Emergent Adverse Event (TEAE) Classification	N=168 Number of Patients with Event at Stated Grade			
Any TEAE	Gr 1: 115 (68.5%) Gr 2: 69 (41.1%) Gr 3: 10 (6.0%) Gr 4: 1 (0.6%)			
TEAE leading to drug/placebo discontinuation	21			
Treatment Emergent Serious Adverse Event (SAE)	11 (all unrelated to study treatment)			
Drug/placebo-related TEAE	Gr 1: 52 (30.1%) Gr 2: 25 (14.9%)			
AE data as of 2 April 2022				

AE data as of 3 April 2023

# NASH Development Program

# Progression from Phase 2b to Phase 3




# We Believe Denifanstat is Differentiated in the Evolving NASH Landsc

	2 <u></u>						
Mechanism	FASN inhibitors	THRß Agonists	FGF-21	GLP-1 agonists	PPAR agonists	ACC inhibitors	
Category	DNL pathway	Nuclear receptor	Growth factor	GLP-1	Nuclear receptor	DNL pathway	l r
Route	Oral	Oral	Le luit	aliut	Oral	Oral	(
Status	Phase 2 ongoing	Phase 3 complete	Phase 2 complete	Phase 2 complete	Phase 3 ongoing	Phase 2 complete	ł
Challenges	• Pending biopsy results	<ul> <li>Selectivity for beta isoform critical to avoid potential heart and bone safety issues</li> </ul>	<ul> <li>Injectable</li> <li>Nausea and diarrhea</li> <li>Potential neutralizing antibodies</li> <li>Higher expected COGS</li> </ul>	<ul> <li>GI side effects including nausea</li> <li>Lack of fibrosis improvement to date</li> </ul>	<ul> <li>Weight gain, edema, GI side effects, anemia</li> </ul>	<ul> <li>Combinations only</li> <li>MOA causes triglyceride increases</li> <li>Lack of fibrosis improvement as monotherapy</li> </ul>	•

20

# Precision Medicine: Blood Tests May Lead to Improved Patient Outco

- NASH is a multi-faceted disease and patients may benefit from being matched with optimal trea
- Two approaches using blood tests are undergoing further evaluation
  - Drug response: 1-2 months after taking drug, tripalmitin identifies patients responding to drug treatment
  - Predictive marker: before taking drug, signature of 6 blood metabolites enriches for responders<sup>1</sup>



<sup>1</sup>Signature has 6 metabolites: ursodeoxycholic acid, DL-2-aminocaprylic acid, sarcosine, glycoursodeoxycholic acid, D(-)-2-aminobutyric acid, PC(0-18:0/22:4). Accuracy 79%, PPV 88%, NPV 63%.

# Strong Monotherapy Opportunity for Denifanstat in NASH


Expansion as backbone of combinations

#### Denifanstat data support success as first line monotherapy

- Oral, once-daily tablet ideal for chronic administration
   Tablets generally more affordable than complex biologics
- Potential to treat broad patient population
   Including those with thyroid challenges
- ✓ Novel mechanism that acts directly upon liver
- ✓ Encouraging safety profile to date

# Broaden market opportunity through combinations with denifanstat as backbone

- Denifanstat's potential
  - Complementary to other mechanisms
  - ✓ Potential for fixed dose combinations with other oral medications
- Preclinical combination studies ongoing
  - NASH agents: anti-fibrotic, other metabolic agents
  - Co-morbidities: diabetes and other cardiovascular agents



22

#### Compensated cirrhotic patients (NASH F4)

- Denifanstat directly targets stellate cells
- Hepatocytes continue to be functional, and patients frequently have increased liver fat
- Next steps
  - Characterize PK profile in patients with impaired hepatic function Phase 1 results in 1Q 24
  - Positive impact on fibrosis in FASCINATE-2
  - Phase 2b/3 trial in NASH-F4

#### Pediatric NASH

- 23% of children with NAFLD have NASH at the time of diagnosis
- Next steps

23

- Compile safety data across all denifanstat studies in young adults including FASCINATE-2
- Nonclinical toxicology study in juvenile animals plan to initiate in 2024
- Phase 2 trial in pediatric NASH

<sup>1</sup> Estes, et al. 2018; <u>http://dx.doi.org/10.1016/j.jhep.2018.05.036</u>


Patients in 2016 <sup>1</sup>		
85.3 million	17.3 million	5.7 millio
1000 March		
NAFL non-alcoholic fatty liver	NASH non-alcoholic steatohepatitis	NASH mod-adv fibrosis F2-F3






# Other Indications

# FASN Hyper-Activity Plays a Key Role in Multiple Diseases Beyond NA



# DNL Pathway Plays a Role in the Pathogenesis of Acne

- Acne is associated with excess sebum production by sebocyte cells in the skin
- Acne resolution is associated with reduced sebum production
- Sebocytes upregulate and rely on DNL/FASN to make sebum
  - >80% of key sebum lipids such as palmitate and sapienic acid produced by DNL/FASN
- => FASN inhibition has potential therapeutic application



Pa

Esler et al., Sci. Transl. Med.11, eaau8465 (2019). Figure adapted from kidshealth.org

26

# FASN is Integral to Tumor Cell Proliferation and Survival


Reprogramed metabolism is one of the hallmarks of cancer

#### **FASN-dependence**

- Certain cancers are dependent on DNL/FASN for proliferation especially downstream of driver oncogenes
  - eg. KRASM in non-small cell lung cancer (NSCLC)
- Strategy -> exploit this vulnerability using FASN inhibition in the combination setting to cause death

#### **Completed Phase 1 provides foundation**


- 136 patients received denifanstat
- Heavily pretreated Phase 1 population
- Recommended Phase 2 dose defined
- Promising clinical activity consistent with proposed mechanism
  - KRASM NSCLC patients had significantly longer duration on study with denifanstat than KRASWT (p<0.02), and 91% KRASM had stable disease



Dietary fatty acids cannot compensat de novo synthesized palmitate

# FASN-Dependent Tumor Types Identified that Meet Core Crite

Program focused on 4 selected tumor types



28

GBM (glioblastoma), HCC (hepatocellular carcinoma), KRASM (mutant KRAS), NSCLC (non small cell lung cancer)

# Strong Financial Position and Intellectual Property Portfolio

#### Financial highlights Nasdaq: SGMT

- ✓ Upsized IPO completed in July 2023 raised \$96.4 million of gross proceeds
- ✓ Cash and equivalents expected to fund current operations into the first quarter of 2025

#### Strong patent estate

- ✓ Composition of matter for denifanstat: 2032
- ✓ Issued in all key commercial territories
- ✓ Opportunities to lengthen exclusivity via Hatch-Waxman and synthesis/formulation applications

# **Development Pipeline: Indications and Clinical Milestones**



30 \* Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China